Laboratory Corporation of America Holdings (NYSE:LH) – Stock analysts at William Blair issued their Q1 2018 earnings estimates for Laboratory Corporation of America Holdings in a research report issued to clients and investors on Tuesday. William Blair analyst A. Murphy anticipates that the medical research company will post earnings per share of $2.41 for the quarter. William Blair also issued estimates for Laboratory Corporation of America Holdings’ Q2 2018 earnings at $2.71 EPS, Q3 2018 earnings at $2.74 EPS and Q4 2018 earnings at $2.66 EPS.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Craig Hallum reiterated a “buy” rating and set a $179.00 price target (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Barclays PLC lifted their price target on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. Jefferies Group LLC reiterated a “hold” rating and set a $170.00 price target (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Wednesday. Finally, ValuEngine upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Laboratory Corporation of America Holdings has a consensus rating of “Buy” and an average target price of $164.00.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/laboratory-corporation-of-america-holdings-lh-to-post-q1-2018-earnings-of-2-41-per-share-william-blair-forecasts.html.

Shares of Laboratory Corporation of America Holdings (LH) traded down 0.50% during mid-day trading on Thursday, hitting $154.44. 48,267 shares of the company’s stock traded hands. The company has a market cap of $15.72 billion, a PE ratio of 21.63 and a beta of 0.94. The firm has a 50-day moving average of $157.04 and a 200 day moving average of $147.47. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter in the previous year, the company posted $2.36 EPS. Laboratory Corporation of America Holdings’s revenue was up 4.9% on a year-over-year basis.

In related news, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the sale, the insider now owns 31,894 shares of the company’s stock, valued at approximately $4,950,586.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lisa J. Uthgenannt sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total transaction of $800,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 222,968 shares of company stock worth $34,980,922. Corporate insiders own 0.90% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Laboratory Corporation of America Holdings by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock worth $1,597,181,000 after acquiring an additional 231,600 shares during the period. BlackRock Inc. increased its holdings in shares of Laboratory Corporation of America Holdings by 3,602.5% in the 1st quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock worth $1,158,430,000 after buying an additional 7,856,297 shares during the last quarter. State Street Corp increased its holdings in shares of Laboratory Corporation of America Holdings by 2.4% in the 1st quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock worth $665,669,000 after buying an additional 109,170 shares during the last quarter. Boston Partners increased its holdings in shares of Laboratory Corporation of America Holdings by 4.8% in the 2nd quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock worth $707,560,000 after buying an additional 210,138 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Laboratory Corporation of America Holdings by 2.0% in the 2nd quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after buying an additional 54,100 shares during the last quarter. 93.21% of the stock is currently owned by institutional investors and hedge funds.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.